3,375,243.0 On Monday US drug maker Eli Lilly said that it will issue voluntary licence to Hyderbad based Natco pharma, ending the legal battle that was brimming over compulsory license for the drug in less than a month. "Natco will be collaborating with Lilly to further accelerate and expand the availability of baricitinib in India during this pandemic, improving the local treatment options available to positively impact the lives of people who are currently battling COVID-19 in India", the company said in a statement. Adding that the company continues to engage in active dialogue with the regulatory authorities and government in India to deliver baricitinib donations through the humanitarian aid organization, Direct Relief and to donate Lilly’s anti-COVID-19 treatments, including Lilly’s neutralizing antibodies.